Otarmeni（lunsotogene parvec-cwha）获美国食品药品监督管理局（FDA）批准，成为首个且唯一的遗传性听力损失基因疗法；Regeneron公司将在美国免费提供Otarmeni。 - Regeneron
Otarmeni (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S. (news.google.com)
